OPKO Health, Inc. OPK
1.72 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:19 PM EST
1.72 0.00 0.00%
After hours · Nov 3, 4:19 PM ET
1.71 Day range 1.81
0.98 52-week range 1.81
- YTD
- +36.51%
- 1 year
- +22.86%
Analyst view
Consensus: buy
Buy
Price target (mean) 4.15 +141.3% upside
Now 1.72
- Target (low)
- 2.25
- Target (mean)
- 4.15
- Target (high)
- 8.50
Ratings (0m) 6 5 buy · 1 hold · 0 sell
- Strong buy3
- Buy2
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.06333 | -0.08 – -0.05 | 0.00 | 0.0% | 136.62M | -9.9% | 3 |
| Next quarter | -0.06 | -0.07 – -0.04 | -0.0358 | -67.6% | 145.48M | -2.0% | 3 |
| Current year | -0.21 | -0.22 – -0.20 | 0.00 | 0.0% | 569.86M | -6.1% | 2 |
| Next year | -0.34333 | -0.48 – -0.26 | -0.21 | -63.5% | 495.12M | -13.1% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Oct 16, 2026 | Barrington Research | Upgrade | Market Perform | Outperform |
| Apr 29, 2026 | Barrington Research | Downgrade | Outperform | Market Perform |
| Mar 2, 2026 | Barrington Research | Maintained | Outperform | Outperform |
| Nov 20, 2025 | JP Morgan | Initiated | — | Neutral |
| Oct 31, 2025 | Jefferies | Downgrade | Buy | Hold |
| Oct 30, 2025 | Barrington Research | Maintained | Outperform | Outperform |
| May 1, 2025 | Barrington Research | Maintained | Outperform | Outperform |
| Apr 25, 2025 | JP Morgan | Initiated | — | Neutral |
| Apr 7, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 19, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 12, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 12, 2025 | Barrington Research | Maintained | Outperform | Outperform |
| Mar 3, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 28, 2025 | Barrington Research | Maintained | Outperform | Outperform |
| Jan 8, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 8, 2024 | Barrington Research | Maintained | Outperform | Outperform |
| Sep 26, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 20, 2024 | Barrington Research | Maintained | Outperform | Outperform |
| Sep 17, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Sep 17, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 8, 2024 | Barrington Research | Maintained | Outperform | Outperform |
| Jul 18, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| May 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 3, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 1, 2024 | Barrington Research | Maintained | Outperform | Outperform |
| Apr 1, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Feb 28, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 28, 2024 | Barrington Research | Maintained | Outperform | Outperform |
| Aug 7, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |